Intensity of de novo DSA detected by Immucor Lifecodes assay and C3d fixing antibodies are not predictive of subclinical ABMR after Kidney Transplantation - Normandie Université Access content directly
Journal Articles PLoS ONE Year : 2021

Intensity of de novo DSA detected by Immucor Lifecodes assay and C3d fixing antibodies are not predictive of subclinical ABMR after Kidney Transplantation

Dominique Bertrand
Rangolie Kaveri
  • Function : Author
Charlotte Laurent
  • Function : Author
Philippe Gatault
  • Function : Author
Maïté Jauréguy
  • Function : Author
Cyril Garrouste
  • Function : Author
Johnny Sayegh
  • Function : Author
Nicolas Bouvier
  • Function : Author
Sophie Caillard
  • Function : Author
Luca Lanfranco
  • Function : Author
Antoine Thierry
  • Function : Author
Françoise Hau
  • Function : Author
Isabelle Etienne
  • Function : Author
Dominique Guerrot
  • Function : Author
Fabienne Farce
  • Function : Author

Abstract

De novo donor-specific antibodies (dnDSA) are associated with antibody-mediated rejection (ABMR) and allograft loss. We tested Immucor* (IM) Luminex Single-antigen beads (LSAB) assay and C3d-fixing antibodies in the setting of dnDSA and subclinical (s) ABMR. This retrospective multicentric study included 123 patients biopsied because of the presence of subclinical de novo DSA detected by One Lamda* Labscreen (MFI > 1000). In 112 patients, sera of the day of the biopsy were available and tested in a central lab with IM Lifecodes LSAB and C3d fixing antibodies assays. In 16 patients (14.3%), no DSA was detected using Immucor test. In 96 patients, at least one DSA was determined with IM. Systematic biopsies showed active sABMR in 30 patients (31.2%), chronic active sABMR in 17 patients (17.7%) and no lesions of sABMR in 49 KT recipients (51%). Intensitity criteria (BCM, BCR and AD-BCR) of DSA were not statistically different between these 3 histological groups. The proportion of patients with C3d-fixing DSA was not statistically different between the 3 groups and did not offer any prognostic value regarding graft survival. Performing biopsy for dnDSA could not be guided by the intensity criteria of IM LSAB assay. C3d-fixing DSA do not offer added value.

Dates and versions

hal-03751893 , version 1 (16-08-2022)

Identifiers

Cite

Dominique Bertrand, Rangolie Kaveri, Charlotte Laurent, Philippe Gatault, Maïté Jauréguy, et al.. Intensity of de novo DSA detected by Immucor Lifecodes assay and C3d fixing antibodies are not predictive of subclinical ABMR after Kidney Transplantation. PLoS ONE, 2021, 16 (4), pp.e0249934. ⟨10.1371/journal.pone.0249934⟩. ⟨hal-03751893⟩
17 View
0 Download

Altmetric

Share

Gmail Facebook X LinkedIn More